Background: Studies on the relationship between BRAF V600E mutation and the clinicopathologic features of papillary thyroid carcinoma (PTC), risk of lymph node metastasis in papillary thyroid microcarcinoma (PTMC) have shown inconsistent results.
Methods: In this retrospective analysis, clinicopathological data of the patients were collected, and molecular testing was done for BRAF V600E mutation. PTC patients are divided into PTC≤ 1.0cm (PTMC) and PTC> 1.0cm, and the relationship between BRAF V600E mutation and clinicopathologic features was analyzed respectively.
Results: Of the 520 PTC patients, 432 (83.1%) were female and 416 (80.0%) were < 55 years old. BRAF V600E mutation was detected in 422 (81.2%) tumour samples of PTC. There was no significant difference in the frequency of BRAF V600E mutation between different age groups. There were 250 (48.1%) patients with PTMC and 270 (51.9%) patients with PTC> 1.0cm. BRAF V600E mutation was significantly associated with bilateral cancer (23.0% vs 4.9%, P =0.005) and lymph node metastasis (61.7% vs 39.0%, P =0.009) in PTMC patients, while BRAF V600E mutation was significantly associated with bilateral cancer (24.9% vs 12.3%, P 0.048) in PTC> 1.0cm patients. Logistic regression analysis showed that, after adjusting for gender, Hashimoto’s thyroiditis and calcification, we found that younger age (< 55 years old) (OR: 2.384, 95% CI: 1.241– 4.579, P =0.009) and BRAF V600E mutation (OR: 2.213, 95% CI: 1.085– 4.512, P =0.029) were significantly associated with lymph node metastasis in PTMC, similar results were not obtained in PTC> 1.0cm.
Conclusion: Younger age (< 55 years old) and BRAF V600E mutation was independent risk factor for lymph node metastasis in PTMC.
Keywords: papillary thyroid carcinoma, papillary thyroid microcarcinoma, BRAF , lymph node metastasis